FDA recall D-0290-2026

Cipla USA, Inc. · Class II · drug

Product

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67

Reason for recall

Presence of Particulate Matter.

Distribution

Nationwide in the USA

Key facts

Status: Ongoing
Initiation date: 2026-01-02
Report date: 2026-01-21
Voluntary/Mandated: Voluntary: Firm initiated
Location: Warren, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0290-2026